Fig. 3.
GPRC5A repression predicts aggressive clinicopathological characteristics and poor prognosis in HNSCC patients. a Representative images (×100 and ×400) of GPRC5A IHC staining in HNSCC with different differentiation grades. b IHC scores of GPRC5A expression for HNSCC of well differentiated (Grade 1), moderately differentiated (Grade 2), and poorly differentiated (Grade 3). c Low GPRC5A expression group shows a relative worse 5-year overall survival (data from Oncomine by Rickman et al.). d Low GPRC5A expression group shows a relative worse 5-year distant metastasis-free survival (data from Oncomine by Rickman et al.)